As of 2025-01-14, the Relative Valuation of Bristol-Myers Squibb Co (BMY) is 4.79 USD. This relative valuation is based on P/E multiples. With the latest stock price at 55.36 USD, the upside of Bristol-Myers Squibb Co based on Relative Valuation is -91.3%.
The range of the Relative Valuation is (99.48) - 146.39 USD.
| Range | Selected | |
| Trailing P/E multiples | 27.8x - 32.8x | 30.4x |
| Forward P/E multiples | 24.9x - 39.8x | 32.2x |
| Fair Price | (99.48) - 146.39 | 4.79 |
| Upside | -279.7% - 164.4% | -91.3% |
| Date | P/E |
| 2025-01-10 | -15.60 |
| 2025-01-08 | -15.88 |
| 2025-01-07 | -15.97 |
| 2025-01-06 | -15.84 |
| 2025-01-03 | -15.81 |
| 2025-01-02 | -15.87 |
| 2024-12-31 | -15.81 |
| 2024-12-30 | -15.67 |
| 2024-12-27 | -16.12 |
| 2024-12-26 | -16.21 |
| 2024-12-24 | -16.14 |
| 2024-12-23 | -16.09 |
| 2024-12-20 | -16.02 |
| 2024-12-19 | -15.73 |
| 2024-12-18 | -15.88 |
| 2024-12-17 | -16.11 |
| 2024-12-16 | -15.61 |
| 2024-12-13 | -15.59 |
| 2024-12-12 | -15.73 |
| 2024-12-11 | -15.83 |
| 2024-12-10 | -16.24 |
| 2024-12-09 | -16.41 |
| 2024-12-06 | -16.59 |
| 2024-12-05 | -16.44 |
| 2024-12-04 | -16.31 |
| 2024-12-03 | -16.40 |
| 2024-12-02 | -16.75 |
| 2024-11-29 | -16.55 |
| 2024-11-27 | -16.56 |
| 2024-11-26 | -16.41 |
| 2024-11-25 | -16.43 |
| 2024-11-22 | -16.45 |
| 2024-11-21 | -16.27 |
| 2024-11-20 | -16.17 |
| 2024-11-19 | -16.27 |
| 2024-11-18 | -15.87 |
| 2024-11-15 | -15.71 |
| 2024-11-14 | -16.35 |
| 2024-11-13 | -16.32 |
| 2024-11-12 | -16.49 |
| 2024-11-11 | -16.72 |
| 2024-11-08 | -15.13 |
| 2024-11-07 | -15.29 |
| 2024-11-06 | -15.45 |
| 2024-11-05 | -15.63 |
| 2024-11-04 | -15.49 |
| 2024-11-01 | -15.18 |
| 2024-10-31 | -15.58 |
| 2024-10-30 | -14.72 |
| 2024-10-29 | -14.67 |